PMID- 11861035
OWN - NLM
STAT- MEDLINE
DCOM- 20020429
LR  - 20190513
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 53
IP  - 3
DP  - 2002 Feb 15
TI  - The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women.
PG  - 642-9
AB  - OBJECTIVE: Monocyte chemoattractant protein-1 (MCP-1) is considered a propagator 
      of atherosclerosis and a key modulator of monocyte activity. Hormone replacement 
      therapy (HRT) is currently being investigated as a means towards prevention of 
      atherosclerosis. We aimed to assess (1) the range of circulating MCP-1 levels in 
      postmenopausal women, (2) the correlation between MCP-1 and atherosclerotic 
      burden, and (3) the effects of commencement and discontinuation of HRT on MCP-1 
      serum levels. METHODS: This clinical prospective trial investigated 51 
      postmenopausal women at increased risk for cardiovascular events who were 
      randomized to receive either no HRT or 1 mg 17 beta-estradiol continuously plus 
      sequential progestagen over 1 year. Intima-media thickness (IMT) of carotid and 
      femoral arteries was measured by ultrasound. Serum levels of MCP-1 and cellular 
      adhesion molecules were measured by ELISA. RESULTS: At baseline, MCP-1 levels and 
      overall mean maximum IMT correlated (r=0.589; P<0.0001, Pearson's coefficient). 
      MCP-1 levels in serum gradually decreased after 3, 6, and 12 months of HRT by 
      16.8 +/- 15.7% at 12 months (P<0.0001, MANOVA). Similarly, all cellular adhesion 
      molecules decreased significantly by 6-12%. After 12 months, women decided 
      whether to continue or discontinue treatment. At 18 months, in women 
      discontinuing HRT (n=17), MCP-1 levels rose by 21 +/- 20% (P=0.003), but remained 
      lowered in women continuing HRT. CONCLUSION: Our observations indicate that 17 
      beta-estradiol may have an antiatherosclerotic effect by reducing MCP-1 serum 
      levels and cell adhesion molecules.
FAU - Stork, Stefan
AU  - Stork S
AD  - Medizinische Klinik, Klinikum der Universitat Munchen - Innenstadt, Ziemssenstr. 
      1, D-80336 Munchen, Germany. s.stoerk@medizin.uni-wuerzburg.de
FAU - Baumann, Klaus
AU  - Baumann K
FAU - von Schacky, Clemens
AU  - von Schacky C
FAU - Angerer, Peter
AU  - Angerer P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Chemokine CCL2)
SB  - IM
CIN - Cardiovasc Res. 2002 Aug 1;55(2):416; author reply 417. PMID: 12123781
MH  - Analysis of Variance
MH  - Arteriosclerosis/blood/diagnostic imaging/*prevention & control
MH  - Carotid Arteries
MH  - Cell Adhesion Molecules/blood
MH  - Chemokine CCL2/*blood
MH  - *Estrogen Replacement Therapy
MH  - Female
MH  - Femoral Artery
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - Tunica Intima/diagnostic imaging
MH  - Ultrasonography
EDAT- 2002/02/28 10:00
MHDA- 2002/05/01 10:01
CRDT- 2002/02/28 10:00
PHST- 2002/02/28 10:00 [pubmed]
PHST- 2002/05/01 10:01 [medline]
PHST- 2002/02/28 10:00 [entrez]
AID - S0008636301004618 [pii]
AID - 10.1016/s0008-6363(01)00461-8 [doi]
PST - ppublish
SO  - Cardiovasc Res. 2002 Feb 15;53(3):642-9. doi: 10.1016/s0008-6363(01)00461-8.